Aquestive Therapeutics, Inc.
AQST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $308,745 | $123,737 | $43,963 | $148,122 |
| - Cash | $71,546 | $23,872 | $27,273 | $28,024 |
| + Debt | $38,004 | $33,319 | $57,488 | $56,421 |
| Enterprise Value | $275,203 | $133,184 | $74,178 | $176,519 |
| Revenue | $57,561 | $50,583 | $47,680 | $50,832 |
| % Growth | 13.8% | 6.1% | -6.2% | – |
| Gross Profit | $39,689 | $29,752 | $28,294 | $35,843 |
| % Margin | 69% | 58.8% | 59.3% | 70.5% |
| EBITDA | -$26,616 | $1,182 | -$39,580 | -$45,114 |
| % Margin | -46.2% | 2.3% | -83% | -88.8% |
| Net Income | -$44,137 | -$7,870 | -$54,410 | -$70,539 |
| % Margin | -76.7% | -15.6% | -114.1% | -138.8% |
| EPS Diluted | -0.51 | -0.13 | -1.12 | -1.85 |
| % Growth | -292.3% | 88.4% | 39.5% | – |
| Operating Cash Flow | -$35,759 | -$6,380 | -$9,789 | -$32,979 |
| Capital Expenditures | -$159 | -$995 | -$2,524 | -$913 |
| Free Cash Flow | -$35,918 | -$7,375 | -$12,313 | -$33,892 |